The Expression and Regulation of Bone-acting Cytokines in Human Peripheral Adipose Tissue in Organ Culture

Abstract

The humoral cross-talk between bone and fat is an area of increasing interest. We investigated the expression and regulation of the bone-acting cytokines; bone morphogenetic protein 2 (BMP2), connective tissue growth factor (CTGF), osteoprotegerin (OPG), and transforming growth factor beta (TGFB1). Subcutaneous adipose tissue was aspirated from lean, healthy women. Tissue samples were incubated with interleukin 1-β (IL1-β), tumor necrosis factor-α (TNF-α), cortisol, troglitazone, IL1-β + troglitazone, or vehicle. Gene expression in the adipose tissue was analyzed using qPCR and protein levels in the incubation media were analyzed using ELISA. OPG expression and secretion was diminished by 40.8% and 43.1% respectively, by cortisol, and OPG expression was diminished by 67.5% by troglitazone (p<0.05). The proinflammatory cytokines IL1-β and TNF-α significantly increased the expression of CTGF (p<0.05) by 65.1% and 101.3%, respectively, and the expression and secretion of OGP by 62.3–165.8% (p<0.05). This interleukin 1-β mediated increase in CTGF- and OPG expression and secretion was ameliorated by troglitazone. Troglitazone and related drugs are known to have adverse effects on bone. We suggest that this could be mediated via altered cytokine production in adipose tissue. Moreover, obese individuals have a low-grade inflammation in their adipose tissue and have higher bone mineral density than lean individuals. We suggest that this inflammation may increase the expression and secretion of OPG and CTGF and thereby increase BMD. In conclusion, bone acting cytokines are produced in the adipose tissue and may affect bone through endocrine mechanisms.

adipose tissue - thiazolidinediones - inflammation - real-time PCR - ELISA

References

• 1 Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.  N Engl J Med. 2003;  348 1656-1663
• 2 Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate?.  Bone. 2004;  35 1192-1199
• 3 Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton.  Cell. 2007;  130 456-469
• 4 Reid IR. Relationships among body mass, its components, and bone.  Bone. 2002;  31 547-555
• 5 Wang MC, Bachrach LK, Van Loan M, Hudes M, Flegal KM, Crawford PB. The relative contributions of lean tissue mass and fat mass to bone density in young women.  Bone. 2005;  37 474-481
• 6 Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, Mori K, Tamura N, Hosoda K, Yoshimasa Y. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue.  Diabetes. 1995;  44 855-858
• 7 Zhao LJ, Liu YJ, Liu PY, Hamilton J, Recker RR, Deng HW. Relationship of obesity with osteoporosis.  J Clin Endocrinol Metab. 2007;  92 1640-1646
• 8 Bonewald LF. Regulation and regulatory activities of transforming growth factor beta.  Crit Rev Eukaryot Gene Expr. 1999;  9 33-44
• 9 Bonewald LF, Mundy GR. Role of transforming growth factor-beta in bone remodeling.  Clin Orthop. 1990;  261-276
• 10 Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs).  J Bone Joint Surg Am. 2003;  85-A 1544-1552
• 11 Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G, Stefansson K. Linkage of osteoporosis to chromosome 20p12 and association to BMP2.  PLoS Biol. 2003;  1 E69
• 12 Plikus MV, Mayer JA, de la CD, Baker RE, Maini PK, Maxson R, Chuong CM. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration.  Nature. 2008;  451 340-344
• 13 Tan JT, McLennan SV, Song WW, Lo LW, Bonner JG, Williams PF, Twigg SM. Connective tissue growth factor inhibits adipocyte differentiation.  Am J Physiol Cell Physiol. 2008;  295 C740-C751
• 14 Hopwood B, Tsykin A, Findlay DM, Fazzalari NL. Gene expression profile of the bone microenvironment in human fragility fracture bone.  Bone. 2009;  44 87-101
• 15 Sims NA, Gooi JH. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption.  Semin Cell Dev Biol. 2008;  19 444-451
• 16 Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.  Endocr Rev. 2008;  29 155-192
• 17 Manolagas SC. Role of cytokines in bone resorption.  Bone. 1995;  (S 02) 63-67
• 18 Silverman SL, Lane NE. Glucocorticoid-induced osteoporosis.  Curr Osteoporos Rep. 2009;  7 23-26
• 19 Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture.  Ann Pharmacother. 2007;  41 2014-2018
• 20 Bruun JM, Pedersen SB, Richelsen B. Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin.  Horm Metab Res. 2000;  32 537-541
• 21 Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.  Genome Biol. 2002;  3 RESEARCH0034
• 22 Fu M, Zhang J, Lin YY, Zhu X, Willson TM, Chen YE. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells.  Biochem Biophys Res Commun. 2002;  294 597-601
• 23 Zhang GY, Yi CG, Li X, Ma B, Li ZJ, Chen XL, Guo SZ, Gao WY. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.  Br J Dermatol. 2009;  160 762-770
• 24 Peng Y, Liu H, Liu F, Liu Y, Li J, Chen X. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.  Nephrology (Carlton). 2006;  11 516-523
• 25 Wei JL, Peng YM, Liu F. Connective tissue growth factor and fibronectin secretion in renal tubular epithelial cells induced by TGF-beta1: suppressive effects of troglitazone.  Cell Biol Int. 2007;  31 30-34
• 26 An JJ, Han DH, Kim DM, Kim SH, Rhee Y, Lee EJ, Lim SK. Expression and regulation of osteoprotegerin in adipose tissue.  Yonsei Med J. 2007;  48 765-772
• 27 Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.  Diabetes Res Clin Pract. 1991;  11 147-153
• 28 Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.  Endocrinology. 2005;  146 1226-1235
• 29 Jones SG, Momin SR, Good MW, Shea TK, Patric K. Distal upper and lower limb fractures associated with thiazolidinedione use.  Am J Manag Care. 2009;  15 491-496
• 30 Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.  N Engl J Med. 2006;  355 2427-2443
• 31 Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.  J Clin Endocrinol Metab. 2007;  92 1305-1310
• 32 Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene.  J Biol Chem. 1997;  272 18779-18789
• 33 Ahdjoudj S, Fromigue O, Marie PJ. Plasticity and regulation of human bone marrow stromal osteoprogenitor cells: potential implication in the treatment of age-related bone loss.  Histol Histopathol. 2004;  19 151-157
• 34 Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors.  J Clin Invest. 2004;  113 846-855
• 35 Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice.  Nat Med. 2007;  13 1496-1503
• 36 Cummings SR, San MJ, McCLung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.  N Engl J Med. 2009;  361 756-765
• 37 Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.  J Lipid Res. 2005;  46 2347-2355
• 38 Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin.  Diabetologia. 2006;  49 744-747
• 39 Rogowski O, Shapira I, Steinvil A, Berliner S. Low-grade inflammation in individuals with the hypertriglyceridemic waist phenotype: another feature of the atherogenic dysmetabolism.  Metabolism. 2009;  58 661-667
• 40 Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts.  Am J Med Sci. 2009;  338 310-318
• 41 Hardy R, Cooper MS. Bone loss in inflammatory disorders.  J Endocrinol. 2009;  201 309-320
• 42 Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.  J Exp Med. 2000;  191 275-286
• 43 Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system.  Endocr Rev. 2008;  29 403-440
• 44 Vestergaard P, Lindholm J, Jorgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Kristensen LO, Feldt-Rasmussen U, Mosekilde L. Increased risk of osteoporotic fractures in patients with Cushing's syndrome.  Eur J Endocrinol. 2002;  146 51-56
• 45 Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men.  J Clin Endocrinol Metab. 1998;  83 801-806
• 46 Cooper MS. Sensitivity of bone to glucocorticoids.  Clin Sci (Lond). 2004;  107 111-123
• 47 Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis [see comments].  Endocrinology. 1999;  140 4382-4389
• 48 Fain JN, Tagele BM, Cheema P, Madan AK, Tichansky DS. Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women.  Obesity (Silver Spring). 2010;  18 890-896
• 49 Kissebah AH, Krakower GR. Regional adiposity and morbidity.  Physiol Rev. 1994;  74 761-811
• 50 Vidal H. Gene expression in visceral and subcutaneous adipose tissues.  Ann Med. 2001;  33 547-555
• 51 Hozumi A, Osaki M, Goto H, Sakamoto K, Inokuchi S, Shindo H. Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation.  Biochem Biophys Res Commun. 2009;  382 780-784

Correspondence